Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Memantine Augmentation in Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks) — 23.8; 30; 13.0; 28.8 units on a scale
Phase 4 N=137 Testosterone Replacement in Men With Diabetes and Obesity
Hypogonadism
Primary: Insulin Sensitivity — 6.66; 5.12; 11.37; 12.93 mg/kg fat free mass/min
Phase 2 N=49 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Phase 4 N=20 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
Obsessive Compulsive Disorder
Primary: Y-BOCS Scores at 1st and Last Visit — 27.45; 20.45 units on a scale
Phase 2 N=86 Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
Dermatitis, Atopic
Primary: Improvement From Baseline in Atopic Dermatitis Severity Index (ADSI) Score at Day 8 — 8.22; 8.02; 8.13; 8.19 units on a scale
Phase 2 N=35 Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
Psoriasis
Primary: Percentage of Participants With Greater Decrease in Overall Target Plaque Severity Score (OTPSS) at Day 28 — 68.6; 5.7 percentage of participants — p=< 0.001
Phase 2 N=18 Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Pulmonary Arterial Hypertension
Primary: Change in Hemodynamic Parameters From Baseline to Week 24. — -2.0; 0; -1.0; 3.0 mmHg
Phase 2 N=32 Healthy Aging Through Functional Food
Glucose Intolerance · Aortic Stiffness · Vasodilation
Primary: Area Under the Curve for Oral Glucose Tolerance Test (oGGT) — 10.8; 11.0; 9.9; 10.6 mM h
Phase 3 N=100 A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
Rheumatoid Arthritis
Primary: Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity — 16.5; 34.1 percentage of participants
Phase 2 N=20 Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Pulmonary Fibrosis
Primary: Incidence of Overall Adverse Events — 12; 8; 11 participants
Phase 2 N=16 Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Non-small Cell Lung Cancer (NSCLC) · Lung Cancer · Neoplasm Metastasis
Primary: Incidence of Central Nervous System (CNS) Hemorrhagic Events — 0 CNS hemorrhagic events
Phase 3 N=397 A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) Time — 9.2; 7.4 months — p=<0.001
Phase 2 N=47 RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Colorectal Cancer
Primary: Progression Free Survival at Six Months — 87 percentage of participants
N/A N=208 Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses
Cataract
Primary: Percentage of Participants Classified as Responders — 45.7; 2.1 percentage of participants